Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug-Drug Interaction (DDI) Study?

Nitrosamine Impurities
N-Nitrosamine impurity findings in marketed formulations of rifampin have disrupted drug development. As a strong cytochrome P450 3A4 (CYP3A4) inducer, rifampin was regularly co-administered with investigational products
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Empower your drug design & synthesis with vibrational circular dichroism (VCD)

Vibrational Circular Dichroism (VCD) is used to determine the absolute configuration of compounds in solution. As a result, it doesn’t require crystalline substances.
Watch Now

The untold benefits of a digital maintenance strategy for pharma

Increasingly, the conventional ways of maintaining pharma equipment call for a digital alternative. Non-wear-based failures such as operating excursion and changes in operation plans make up to 80% of equipment failures.
Watch Now

Utilizing NGS for Proteomics - Olink® to Accelerate Drug Discovery and Optimize Clinical Trials Outcome

The future of healthcare will change for the better by adding more tailored treatment options, where patients get the best medication related to their disease state and predisposition.
Watch Now

Osteosarcoma research

Thermo Fisher Scientific

Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.
Watch Now